Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

被引：0
|
作者：
Touzeau, Cyrille
Moreau, Philippe
Perrot, Aurore
Hulin, Cyrille
Dib, Mamoun
Tiab, Mourad
Caillot, Denis
Facon, Thierry
Leleu, Xavier
van de Donk, Niels W. C. J.
Broijl, Annemiek
Zweegman, Sonja
Levin, Mark-David
Delforge, Michel
Pei, Lixia
Vanquickelberghe, Veronique
De Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Sonneveld, Pieter
机构：
[1] Ctr Hosp Univ, Nantes, France
[2] Univ Hosp Hotel Dieu, Hematol, Nantes, France
[3] Univ Canc Inst IUCT, Hematol Dept, Toulouse, France
[4] Univ Hosp Bordeaux, Dept Hematol, Hop Haut Leveque, Pessac, France
[5] CHRU, Hop Bocage, Angers, France
[6] CHD Vendee, La Roche Sur Yon, France
[7] CHU Dijon, Hop Bocage, Dijon, France
[8] Univ Lille, Serv Malad Sang, CHU Lille, Lille, France
[9] CHU Poitiers, Hop Miletrie, Poitiers, France
[10] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[11] Erasmus MC, Canc Inst, Rotterdam, Netherlands
[12] Albert Schweitzer Hosp, Dordrecht, Netherlands
[13] Univ Ziekenhuizen Leuven, Leuven, Belgium
[14] Janssen Res & Dev LLC, Raritan, NJ USA
[15] Janssen Res & Dev, Beerse, Belgium
[16] Janssen Res & Dev LLC, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8538
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
    Voorhees, Peter
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano
    Anderson, Larry
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E353 - E354
  • [22] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [23] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
  • [24] A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexameth-asone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Leleu, Xavier
    Hulin, Cyrille
    Hashim, Mahmoud
    Hu, Yannan
    Cote, Sarah
    Kampfenkel, Tobias
    de Boer, Carla
    Lam, Annette
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E199 - E200
  • [25] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
    Sonneveld, Pieter
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Sureda Balari, Anna
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Driessen, Christoph
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Boccadoro, Mario
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
  • [26] Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Rosinol Dachs, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Rios, Rafael
    Hulin, Cyrille
    Jesus Blanchard, Maria
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel T.
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus F.
    Belhadj, Karim
    Jose Lahuerta, Juan
    Chen, Guang
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    Attal, Michel
    BLOOD, 2018, 132
  • [27] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
    Rodriguez-Otero, Paula
    Moreau, Philippe
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Perrot, Aurore
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels W. C. J.
    Schjesvold, Fredrik
    Delforge, Michel
    Einsele, Hermann
    Spencer, Andrew
    Lonergan, Sarah
    Vieyra, Diego
    Sitthi-Amorn, Anna
    Carson, Robin L.
    Blade, Joan
    Boccadoro, Mario
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
    Chari, Ajai
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 7278 - 7281
  • [29] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
    Wang, Yin-Che
    Lin, Cheng-Hsien
    Su, Yu-Chen
    Teng, Chieh-Lin Jerry
    HEMATOLOGY, 2025, 30 (01)
  • [30] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Santos, Juliana Andrade
    de Melo Santos, Herbert Henrique
    Santos, Allan de Souza
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Chaves, Marcos
    Dutra, Daniela Dourado
    Hungria, Vania T. M.
    Salvino, Marco Aurelio
    Arruda, Maria da Gloria B.
    BLOOD, 2022, 140 : 7699 - 7700
12345